OncRef

Clinical Trial: NCT03141177

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2026-08-24

Study Overview

Brief Summary

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Official Title

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Conditions

Renal Cell Carcinoma

Intervention / Treatment

  • Biological: Nivolumab
  • Drug: Cabozantinib
  • Drug: Sunitinib
  • Biological: Ipilimumab

Other Study ID Numbers

  • CA209-9ER
  • 2017-000759-20
  • 2017

Start Date (Actual)

2017-07-23

Primary Completion Date (Actual)

2020-02-12

Study Completion Date (Actual)

2026-04-01

Enrollment (Actual)

701

Study Type

Interventional

Phase

Phase 3